Periodic Reporting for period 1 - CORLID (Cortical markers of L-DOPA-induced dyskinesias)

Parkinson’s disease (PD) is a neurodegenerative disorder that affects about 1% of the population over 55. After more than 50 years, dopaminergic treatment is still the gold standard in PD therapy, although, as the disease progresses, several motor complications may arise...